Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - Here's What Happened

Key Points

• Chugai Pharmaceutical shares experienced a 4.2% decline, starting the trading session at $24.05 compared to the previous close of $24.93.
• The company reported $0.20 earnings per share for the previous quarter, with total revenue of $2.01 billion.
• Chugai Pharmaceutical has a market capitalization of $78.62 billion and a PE ratio of 30.24.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $24.93, but opened at $24.05. Chugai Pharmaceutical shares last traded at $24.01, with a volume of 16,995 shares traded.

Chugai Pharmaceutical Stock Down 4.2%

The company has a 50-day simple moving average of $22.55 and a two-hundred day simple moving average of $24.40. The firm has a market cap of $78.62 billion, a PE ratio of 30.24 and a beta of 0.64.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. The business had revenue of $2.01 billion for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. As a group, equities analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.